SEC Form 4 · accession 0001209191-17-044704
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Petrus Bekker
Officer — Chief Medical Officer
Period of report
Jul 7, 2017
Accepted (ET)
Jul 10, 2017 · 7:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2017 | M | 19,587 | $6.30 | A | 79,426 | D | |
| Common Stock | Jul 7, 2017 | S | 19,587 | $9.30 | D | 59,839 | D | |
| Common Stock | Jul 10, 2017 | M | 290 | $6.30 | A | 60,129 | D | |
| Common Stock | Jul 10, 2017 | S | 290 | $9.30 | D | 59,839 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $6.30 | Jul 7, 2017 | M | 19,587 | D | — | Aug 10, 2020 | Common Stock | 19,587 | 10,164 | D |
| Stock Option (right to buy)F3,F2 | $6.30 | Jul 10, 2017 | M | 290 | D | — | Aug 10, 2020 | Common Stock | 290 | 9,874 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2As of July 7, 2017, and prior to this transaction, the exercised options were fully vested.
- F3Not applicable.